exp7711 has been researched along with exp3174 in 6 studies
| Studies (exp7711) | Trials (exp7711) | Recent Studies (post-2010) (exp7711) | Studies (exp3174) | Trials (exp3174) | Recent Studies (post-2010) (exp3174) |
|---|---|---|---|---|---|
| 18 | 0 | 1 | 236 | 29 | 43 |
| Protein | Taxonomy | exp7711 (IC50) | exp3174 (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.0013 | |
| Type-1A angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0027 | |
| Type-1B angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0036 | |
| Type-1 angiotensin II receptor | Homo sapiens (human) | 0.002 | |
| Type-2 angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0075 | |
| 5-hydroxytryptamine receptor 1A | Mus musculus (house mouse) | 0.0075 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (66.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Belvisi, L; Caliari, S; Canevotti, R; Cirillo, R; Fici, F; Paleari, F; Poma, D; Renzetti, AR; Salimbeni, A; Subissi, A | 1 |
| Ashton, WT; Cantone, CL; Chang, LL; Chang, RS; Chen, TB; Faust, KA; Hutchins, SM; Lotti, VJ; MacCoss, M; Strelitz, RA | 1 |
| Amemiya, Y; Fujimoto, K; Furukawa, Y; Ikeda, M; Kanazaki, T; Kitahara, Y; Koike, H; Miyamoto, S; Mizuno, M; Sada, T; Shimoji, Y; Yanagisawa, H | 1 |
| Goldberg, MR; Greenlee, WJ; Irvin, JD; Prendergast, K; Smith, RD; Timmermans, PB; Wexler, RR | 1 |
| Krovat, EM; Langer, T | 1 |
| Berellini, G; Cruciani, G; Mannhold, R | 1 |
1 review(s) available for exp7711 and exp3174
| Article | Year |
|---|---|
Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Humans; Receptors, Angiotensin; Structure-Activity Relationship | 1996 |
5 other study(ies) available for exp7711 and exp3174
| Article | Year |
|---|---|
N-3-substituted pyrimidinones as potent, orally active, AT1 selective angiotensin II receptor antagonists.
Topics: Administration, Oral; Angiotensin Receptor Antagonists; Animals; Humans; Hypertension; Male; Models, Molecular; Molecular Conformation; Molecular Structure; Pyrimidinones; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Thiophenes | 1995 |
Nonpeptide angiotensin II antagonists derived from 4H-1,2,4-triazoles and 3H-imidazo[1,2-b][1,2,4]triazoles.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta; Binding, Competitive; Blood Pressure; Male; Molecular Structure; Rabbits; Rats; Rats, Sprague-Dawley; Receptors, Angiotensin; Structure-Activity Relationship; Triazoles | 1993 |
Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds.
Topics: Acetylation; Adrenal Cortex; Amino Acid Sequence; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biological Availability; Cattle; Imidazoles; In Vitro Techniques; Kinetics; Male; Models, Molecular; Molecular Conformation; Molecular Sequence Data; Molecular Structure; Rats; Rats, Wistar; Receptors, Angiotensin; Structure-Activity Relationship | 1996 |
Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification.
Topics: Acrylates; Algorithms; Angiotensin II; Biphenyl Compounds; Databases, Factual; Imidazoles; Lactones; Losartan; Models, Molecular; Molecular Conformation; Pyridines; Quantitative Structure-Activity Relationship; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Sulfones; Tetrazoles; Thiophenes | 2003 |
Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Binding Sites; Biphenyl Compounds; Kinetics; Losartan; Models, Molecular; Molecular Conformation; Oxidation-Reduction; Pharmaceutical Preparations; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Structure-Activity Relationship; Tetrazoles | 2005 |